Member Info for chester18

We don't know the structure of the Milestone payments but the first trigger would probably be GenMab announcing a Phase 1 trial using our Target Mab.

At the end of April it is 6 months since the deal was signed with GenMab and they had approximately 3 years of testing before they agreed to that deal. Is 6 months enough time to prep for a trial ?

Chester.

After a full and exhaustive Due Diligence, Vulpes was the first large investment vehicle to commit many millions of pounds.

Would Redmile have come along with their £40M without them ?
Its really difficult to know for sure, so I always see Vulpes as the initial Green Light investor.

Why would Vulpes release such a document today, two days prior to the lifting of the AACR embargo of the Presentation details ? I see this as a well timed and coordinated build up to our next ModiFY RNS.

The tone taken by this report is extremely positive and I do hope it's because they know 'a little to a lot' more than our good selves. The Embargo lifts on Friday, I've no idea what time of day, with the Lindy Durrant presentation nest Tuesday, so its been released in very short notice to the main event.

Speculation is rife and right now we have very good cause.

Good luck to all shareholders Recent or Long Term, a very successful Scancell is all that we wish for, that's not much to ask for is it....... : )

Chester.

I agree C11

I did put that post out in just a few minutes and I've not explained that point very well.

That trial info was good back in February but we are now waiting for :
The number of patients currently enrolled and dosed.
What is the split re-tumour types.
Status of the original 14 patients.
How is the enrolment going in the Cohort3 + CPi.
Did the biopsy of the Cohort2 patients tumour happen and what were the results.
Have BionTech been supplied with the ModiFy enhanced 'T' Cells and do we have any feedback from them.

So many questions that could now be answered.

Chester.

Thank you Rob

Being invested in Scancell has taught us to be cautiously optimistic but the current trial circumstances should allow us to be more an just hopeful for a positive AACR outcome.

There are a few pointers that we can use :

The 16 week data 'should' be available.
We have received only the basic information so far about how the ModiFy Trial is progressing.
We have already done a deal to enable Modi2 to move into a clinical trial in 2024.
The lack of Scancell seeking media attention even when the potential $600m GenMab deal was announced.

Most importantly, it would seem that there is no rush to engage on the path towards some form of funding. No attempts to massage the share price in readiness for a placing, it feels like they already have that covered.

Take all of these items, add to them the quality of our new Chairman and in my mind it says that Scancell Trial news will arrive to enhance this AACR Presentation.

Therefore positive expectation should be allowed and proved correct.

Chester.

The quote from LD regards to the intention to do a Biopsy of Cohort 2's first patients Tumour.

Prior to 18th there is the opportunity to RNS not just the compiled 16 Week Scan Data but also the results from that Biopsy.

If the penetration of the CD4 'T' Cells is clearly evident in that Biopsy and is ready to be reported then all the large Biotech and Pharma companies will be fully attentive to everything Lindy has to say in her presentation.

We have waited a long time for that transformational RNS to land. Is this the moment when it finally happens ?

It is certainly a very great possibility.

Chester.

I am hoping for a Scancell RNS just prior to the 18th.

It would be unfortunate to go all the way to the US and then announce positive 14 week data the day you return to the UK.

That would be a very great opportunity missed and somehow I don't think LD would pass up the chance to discuss the most recent ( given that they are positive ) results post the AACR Presentation.

Chester.

RW excellent reminders as to why we were all so excited by the AGM. Our little £1 Baby Bio-Tech could be on the threshold of another big step forward.

Let's hope so, fingers and toes crossed....

Chester.

An updated and positive ModiFY update RNS just prior to the Presentation on the 18th would add more than a little spice to the attention Scancell will receive at AACR.

If that is allowed ?

Chester.

Sorry JB1 posts crossed, but we are on the same page, which is good to know.

Chester.

Hi C11

I'm not sure how much actual time there is to do the analysis but the scan measurements can be taken virtually as the data is produced. All the blood works for the trial are probably pushed through the labs in a few days.

I would think the first 10 - 12 patients scans and data will be completed this coming week or just after Easter Monday.

All of this is just logical thinking as we have no way to find out all the actual scan dates.

The main point is that Scancell 'should' have all the 16 week compiled data for those first 14 patients before they even leave for the USA.

Chester.

Hi JB
I totally agree with your post.

When I did the same exercise I guessed that for the data / figures to be released on the 21st Feb Scancell must have had the data from the 14th patient at least two weeks earlier. Ensuring that the data was accurate, checked and double checked before that RNS release.

So my take is that all the 16 week scans will be completed and verified much more quickly as it's just adding that final patient scan to the files already generated.

I would therefore expect Scancell to have all that data in hand just after the easter break, around the 14th April latest.

I'm convinced it will not be all last minute...

Chester.

Oh for the good days Ray.

Getting back home early on a Friday night to catch up on the inevitable heavy weight spats. When we had no trials going and any random theories could championed by someone from either side of the void.

Now all we have are facts and then the wait for the next set of facts. Its just not the same ...... so to ease the boredom, the old tried and trusted 'how are we going to keep the lights on' gambit, gets a dusting off and sent back out in new attire.

So many facts yet to arrive and maybe some juicy ones this month.

Chester......... : )

Being very pragmatic, I'm viewing April as a pivitol month, for three good reasons.

ISA's can be loaded up with cheaper shares due to the recent retrace. Thank you Ichor.

ModiFY trial to yield 16 week scan data.

LD to present new data at a very prestigious event.

It would be very comforting to see a positive RNS every week but in the real world one or two a month is about the norm.

I realise that the 18th could be a very slight improvement on the initial ModiFY RNS but it is also very possible that the data being shared that day will of the kind that moves the SP northwards and puts a smile on all our faces.

Chester.

Hi PaulBrains

Redmile will give all the guidance that our BOD need regarding finance. It is their £40million that's being spent on turning our science ideas into valuable technologies.

I'm sure Redmile will be very aware of the need to generate more capital to continue the ModiFY Trial, the iSCIB+ Trial, the 2024 Modi 2 Trial and the 2024 TCB Antibodies Trial, all announced by Scancell.

Given the ambition of Scancell to run 4 Trials next year you would expect the font of that funding to be fully understood and realised.

The AACR Presentation will set the tone for what is expected, trials wise, for the rest of 2023.

Another deal on GlyMabs would be nice.
We have three collaborations outstanding :
a Chinese BioTech (Dec 2019),
a USA based Clinical StagecAntibody Co. Possibly Seagen Inc. (Jan 2020), and
a Major European Pharma (Mar 2022).

Plus there are other possible routes to cash which we know about.

Chester.

Exactly.

At some point the ModiFY Trial will produce a set of results that will show if its a blockbuster technology or its a good technology that needs some more tweaks.
I'm hopeful that it will be the former.

On the day that we received such an RNS the number of shares you own will be far more valuable than any you have sold for a profit in the past.

It may happen in a 'utopian world' that the company is sold 'lock stock and barrel' at a very handsome price tag, if that happens there will be many saying 'if only I'd kept those shares'.

It won't be me.

Chester.

As you know WTP

If you or I had sold at 28p the SP would have gone up.........!!

It's the Law.....

Chester.

For a start Ichor dumping 3.5m shares at around 16p dragged the SP down and then the sentiment changed to negative.

I cannot see on what basis, if you are invested, would you be nervous. Those trading probably didn't do to well and now those that don't quite understand just how far the science has been validated are beginning to get jumpy.

The fact that all financial markets are somewhat nervous means that any non cash producing shares ( and especially on the Aim Market ) are seen as more risky.

Scancell is moving through the gears with their 4 technology platforms, 3 trials and one 'over the line' deal.

I'm content to see what comes out in the next 12 ( market open ) days and as Flakey says on the 6th April £20k of shares can be transfered to an ISA. At 15.5p that's around 120,000 non taxable shares.

For me I can only see the current status of the company as positive.

Please do your own research and if you do you may find that you agree with my positive stance.

Chester.

Hi JB1

I am now hoping we don't see Scancell listed on the 14th.
That would something.

Chester.

Morning C11

Agreed, I think there have been two occasions where you would normally expect a Proactive Investors type interview that have been passed up.

The GenMab License was an ideal opportunity and the Initial ModiFY Safety and Immunogenicity report especially the partial response and stable patient outcomes.

Chester.

Through their reluctance to do any one to one interviews or RNS news worthy items ( like the AACR presentation ) Scancell have shown a definite Strategy.

We can only conclude that everything is being kept under wraps and these are coordinated and deliberate decisions.

As we have discussed before, we are not party to all the discussions or interest being shown in our platforms by larger BioTech companies.

I'm hoping that this run up to the AACR attendance and presentation on the 18th April is when we begin to understand what is behind the current lack of PR.

Chester.